ibleedblue80
New Member
Jerusalem, Israel: Cannabinoids have antiproliferative effects on cancer cells and may one day represent a new class of anti-cancer drugs, according to a scientific review published in the October issue of the journal Mini-Reviews in Medicinal Chemistry.
The administration of cannabinoids and endocannabinoids - particularly in larger concentrations - have been shown to inhibit cancer cell growth in rodents and in human cell lines, including the inhibition of lung carcinoma, glioma (brain tumors), lymphoma/leukemia, skin carcinoma, colorectal cancer, prostate cancer, and breast cancer, the review found. It noted that cannabinoids, including the non-psychotropic cannabinoid CBD (cannabidiol), appear particularly capable of killing glioma cells by causing apoptosis (programmed cell death). Glioma brain tumors are an aggressive, lethal form of brain cancer that is typically unresponsive to traditional cancer treatments.
"Cannabinoids possess some anticancer activity [and may] possibly represent a new class of anti-cancer drugs that retard cancer growth, inhibit angiogenesis (the formation of new blood vessels), and the metastatic spreading of cancer cells," the review concluded.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, "Cannabinoids and cancer," appears in the October issue of Mini-Reviews in Medicinal Chemistry.
The administration of cannabinoids and endocannabinoids - particularly in larger concentrations - have been shown to inhibit cancer cell growth in rodents and in human cell lines, including the inhibition of lung carcinoma, glioma (brain tumors), lymphoma/leukemia, skin carcinoma, colorectal cancer, prostate cancer, and breast cancer, the review found. It noted that cannabinoids, including the non-psychotropic cannabinoid CBD (cannabidiol), appear particularly capable of killing glioma cells by causing apoptosis (programmed cell death). Glioma brain tumors are an aggressive, lethal form of brain cancer that is typically unresponsive to traditional cancer treatments.
"Cannabinoids possess some anticancer activity [and may] possibly represent a new class of anti-cancer drugs that retard cancer growth, inhibit angiogenesis (the formation of new blood vessels), and the metastatic spreading of cancer cells," the review concluded.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, "Cannabinoids and cancer," appears in the October issue of Mini-Reviews in Medicinal Chemistry.
